

1 State of Arkansas
2 89th General Assembly
3 Regular Session, 2013
4

A Bill

HOUSE BILL 1415

5 By: Representative Vines
6 By: Senator Maloch
7

For An Act To Be Entitled

9 AN ACT CONCERNING SCHEDULING A CONTROLLED SUBSTANCE
10 AS A SCHEDULE VI CONTROLLED SUBSTANCE; AND FOR OTHER
11 PURPOSES.
12
13

Subtitle

14 CONCERNING SCHEDULING A CONTROLLED
15 SUBSTANCE AS A SCHEDULE VI CONTROLLED
16 SUBSTANCE.
17
18
19

20 BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF ARKANSAS:
21

22 SECTION 1. Arkansas Code § 5-64-215 is amended to read as follows:
23 5-64-215. Substances in Schedule VI.

24 (a) In addition to any substance placed in Schedule VI by the Director
25 of the Department of Health under § 5-64-214, any material, compound,
26 mixture, or preparation, whether produced directly or indirectly from a
27 substance of vegetable origin or independently by means of chemical
28 synthesis, or by a combination of extraction and chemical synthesis, that
29 contains any quantity of the following substances, or that contains any of
30 their salts, isomers, and salts of isomers when the existence of the salts,
31 isomers, and salts of isomers is possible within the specific chemical
32 designation, is included in Schedule VI:

- 33 (1) Marijuana;
- 34 (2) Tetrahydrocannabinols;
- 35 (3) A synthetic equivalent of:

36 (A) The substance contained in the Cannabis plant; or



1 (B) The substance contained in the resinous extractives of
2 the genus Cannabis;

3 ~~(4) A substance with the chemical structure of:~~
4 ~~(A) 5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol or~~
5 ~~otherwise known by CP-47,497;~~

6 ~~(B) 5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-~~
7 ~~phenol or otherwise known by either cannabicyclohexanol or CP-47,497-G8~~
8 ~~homologue;~~

9 ~~(C) 1-Butyl-3-(1-naphthoyl)indole or otherwise known by~~
10 ~~JWH-073;~~

11 ~~(D) 1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole or~~
12 ~~otherwise known by JWH-200;~~

13 ~~(E) 1-Pentyl-3-(1-naphthoyl)indole or otherwise known by~~
14 ~~JWH-018 and AM678;~~

15 ~~(F) (4-methoxy-1-naphthalenyl)(1-pentyl-1H-indol-3-yl)-~~
16 ~~methanone or otherwise known by JWH-081; or~~

17 ~~(G) 1-(1-pentyl-1H-indol-3-yl)-2-(2-methoxyphenyl)-~~
18 ~~ethanone or otherwise known by JWH-250;~~

19 ~~(5)(4)~~ Salvia divinorum or Salvinorin A, which includes all
20 parts of the plant presently classified botanically as Salvia divinorum,
21 whether growing or not, the seeds of the plant, any extract from any part of
22 the plant, and every compound, manufacture, derivative, mixture, or
23 preparation of the plant, its seeds, or its extracts, including salts,
24 isomers, and salts of isomers when the existence of the salts, isomers, and
25 salts of isomers is possible within the specific chemical designation; ~~or~~

26 (5) Synthetic substances, derivatives, or their isomers in the
27 chemical structural classes described below in subdivisions (a)(5)(A)-(J) of
28 this section and also specific unclassified substances in subdivision
29 (a)(5)(K) of this section. Compounds of the structures described in this
30 subdivision (a)(5), regardless of numerical designation of atomic positions,
31 are included in this subdivision (a)(5). The synthetic substances,
32 derivatives, or their isomers included in this subdivision (a)(5) are:

33 (A)(i) Tetrahydrocannabinols, including without limitation
34 the following:

35 (a) Delta-1 cis or trans tetrahydrocannabinol,
36 and its optical isomers;

1 (b) Delta-6 cis or trans tetrahydrocannabinol,
 2 and its optical isomers; and

3 (c) Delta-3.4 cis or trans
 4 tetrahydrocannabinol, and its optical isomers.

5 (ii) Dronabinol in sesame oil and encapsulated in a
 6 soft gelatin capsule in a drug product approved by the United States Food and
 7 Drug Administration is not a tetrahydrocannabinol under this subdivision
 8 (a)(5)(A).

9 (B) Naphthoylindoles, or any compound structurally derived
 10 from 3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane by
 11 substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl,
 12 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl
 13 or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the
 14 indole ring to any extent and whether or not substituted in the naphthyl ring
 15 to any extent, including without limitation the following:

16 (i) JWH-007, or 1-pentyl-2-methyl-3-(1-
 17 naphthoyl)indole;

18 (ii) JWH-015, or 1-Propyl-2-methyl-3-(1-
 19 naphthoyl)indole;

20 (iii) JWH-018, or 1-Propyl-3-(1-naphthoyl)indole;

21 (iv) JWH-019, or 1-Hexyl-3-(1-naphthoyl)indole;

22 (v) JWH-073, or 1-Butyl-3-(1-naphthoyl)indole;

23 (vi) JWH-081, or 1-Pentyl-3-(4-methoxy-1-
 24 naphthoyl)indole;

25 (vii) JWH-098, or 1-pentyl-2-methyl-3-(4-methoxy-1-
 26 naphthoyl)indole;

27 (viii) JWH-122, or 1-Pentyl-3-(4-methyl-1-
 28 naphthoyl)indole;

29 (ix) JWH-164, or 1-pentyl-3-(7-methoxy-1-
 30 naphthoyl)indole;

31 (x) JWH-200, or 1-[2-(4-morpholinyl)ethyl]-3-(1-
 32 naphthoyl)indole;

33 (xi) JWH-210, or 1-Pentyl-3-(4-ethyl-1-
 34 naphthoyl)indole;

35 (xii) JWH-398, or 1-Pentyl-3-(4-chloro-1-
 36 naphthoyl)indole;

1 (xiii) AM-2201, or 1-(5-fluoropentyl)-3-(1-
2 naphthoyl)indole;

3 (xiv) MAM2201, or (1-(5-fluoropentyl)-1H-indol-3-
4 yl)(4-methyl-1-naphthalenyl)-methanone; and

5 (xv) EAM2201, or (1-(5-fluoropentyl)-1H-indol-3-
6 yl)(4-ethyl-1-naphthalenyl)-methanone;

7 (C) Naphthylmethylindoles, or any compound structurally
8 derived from an H-indol-3-yl-(1-naphthyl) methane by substitution at the
9 nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl,
10 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-
11 morpholinyl)ethyl group, whether or not further substituted in the indole
12 ring to any extent and whether or not substituted in the naphthyl ring to any
13 extent, including without limitation the following:

14 (i) JWH-175, or 1-Pentyl-1H-indol-3-yl-(1-
15 naphthyl)methane; and

16 (ii) JWH-184, or 1-Pentyl-1H-3-yl-(4-methyl-1-
17 naphthyl)methane;

18 (D) Naphthoylpyrroles, or any compound structurally
19 derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of
20 the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
21 cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl
22 group, whether or not further substituted in the pyrrole ring to any extent
23 and whether or not substituted in the naphthyl ring to any extent, including
24 without limitation JWH-307, or (5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-
25 naphthalen-1-ylmethanone;

26 (E) Naphthylmethylindenes, or any compound structurally
27 derived from 1-(1-naphthylmethyl)indene with substitution at the 3-position of
28 the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
29 cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl
30 group, whether or not further substituted in the indene ring to any extent
31 and whether or not substituted in the naphthyl ring to any extent, including
32 without limitation JWH-176, or E-1-[1-(1-Naphthalenylmethylene)-1H-inden-3-
33 yl]pentane;

34 (F) Phenylacetylindoles, or any compound structurally
35 derived from 3-phenylacetylindole by substitution at the nitrogen atom of the
36 indole ring with alkyl, haloalkyl, alkenyl, cycloalkylmethyl,

1 cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl
2 group, whether or not further substituted in the indole ring to any extent
3 and whether or not substituted in the phenyl ring to any extent, including
4 without limitation the following:

5 (i) JWH-201, or 2-(4-methoxyphenyl)-1-(1-
6 pentylindol-3-yl)ethanone;

7 (ii) JWH-203, or 1-Pentyl-3-(2-
8 chlorophenylacetyl)indole;

9 (iii) JWH-250, or 1-Pentyl-3-(2-
10 methoxyphenylacetyl)indole;

11 (iv) JWH-251, or 1-Pentyl-3-(2-
12 methylphenylacetyl)indole; and

13 (v) RCS-8, or 1-(2-cyclohexylethyl)-3-(2-
14 methoxyphenylacetyl)indole;

15 (G) Cyclohexylphenols, or any compound structurally
16 derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position
17 of the phenolic ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
18 cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl
19 group, whether or not substituted in the cyclohexyl ring to any extent,
20 including without limitation the following:

21 (i) CP 47,497 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-
22 hydroxycyclohexyl]-phenol;

23 (ii) Cannabicyclohexanol or CP47,497 C8homologue, or
24 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol; and

25 (iii) CP55,940, or 5-(1,1-dimethylheptyl)-2-
26 [(1R,2R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-phenol;

27 (H) Benzoylindoles, or any compound structurally derived
28 from a 3-(benzoyl)indole structure with substitution at the nitrogen atom of
29 the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
30 cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl
31 group, whether or not further substituted in the indole ring to any extent
32 and whether or not substituted in the phenyl ring to any extent, including
33 without limitation the following:

34 (i) AM-694, or 1-(5-fluoropentyl)-3-(2-
35 iodobenzoyl)indole;

36 (ii) RCS-4, or 1-Pentyl-3-(4-methoxybenzoyl)indole;

1 (iii) WIN-48,098 or Pravadoline, or (4-
2 Methoxyphenyl)-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]methanone;

3 (iv) AM-2233, or 1-[(N-methylpiperidin-2-yl)methyl]-
4 3-(2-iodobenzoyl)indole; and

5 (v) RCS-4 (c4 homologue) or (4-methoxyphenyl)(1-
6 butyl-1H-indol-3-yl)-methanone;

7 (I) Adamantoylindoles, or Adamantoylindazoles, including
8 Adamantyl Carboxamide Indoles and Adamantyl Carboxamide Indazoles, or any
9 compound structurally derived from 3-(1-adamantoyl) indole, 3-(1-adamantoyl)
10 indazole, or 3-(2-adamantoyl)indole by substitution at a nitrogen atom of the
11 indole or indazole ring with alkyl, haloalkyl, alkenyl, cyanoalkyl,
12 hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-
13 piperidinyl)methyl or 2-(4-morpholinyl)ethyl, whether or not further
14 substituted in the indole or indazole ring to any extent and whether or not
15 substituted in the adamantyl ring to any extent, including without limitation
16 the following:

17 (i) AM-1248, or 1-adamantyl-[1-[(1-methylpiperidin-
18 2-yl)methyl]indol-3-yl]methanone;

19 (ii) AB-001, or 1-adamantyl-(1-pentylindol-3-
20 yl)methanone;

21 (iii) 2NE1, or 1-pentyl-3-(1-adamantylamido)indole;

22 (iv) JWH-018 adamantyl carboxamide, or 1-pentyl-N-
23 tricyclo[3.3.1.1^{3,7}]dec-1-yl-1H-indole-3-carboxamide; and

24 (v) AKB-48, or N-(1-adamantyl)-pentyl-1H-indazole-3-
25 carboxamide;

26 (vi) 5F-AKB-48, or N-((3s,5s,7s)-adamantan-1-yl)-1-
27 (5-fluoropentyl)-1H-indazole-3-carboxamide;

28 (vii) STS-135, or N-(1-adamantyl)-1-(5-
29 fluoropentyl)indole-3-carboxamide;

30 (J) Tetramethylcyclopropylcarbonylindoles or any compound
31 structurally derived from 3-(2,2,3,3-tetramethylcyclopropylcarbonyl) indole
32 by substitution at the nitrogen atom of the indole ring with alkyl,
33 haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl,
34 cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl,
35 whether or not further substituted in the indole ring to any extent,
36 including without limitation the following:

- 1 (i) UR-144, or (1-pentylindol-3-yl)-(2,2,3,3-
2 tetramethylcyclopropyl)methanone;
- 3 (ii) XLR11, or [1-(5-fluoropentyl)-1H-indol-3yl]-
4 (2,2,3,3-tetramethylcyclopropyl)methanone;
- 5 (iii) A-796260, or [1-(2-morpholin-4-yl-ethyl)-1H-
6 indol-3-yl]-(2,2,3,3-tetramethylcyclopropyl)methanone;
- 7 (iv) 5-Chloro-UR-144, or ([-(5-chloropentyl)-1H-
8 indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone;
- 9 (v) 5-Bromo-UR-144, or [1-(5-bromopentyl)-1H-indol-
10 3-yl](2,2,3,3-tetramethylcyclopropyl)methanone; and
- 11 (vi) A-834 735, or 1-(tetrahydropyran-4-ylmethyl)-
12 1H-indol-3-yl]-(2,2,3,3-tetramethylcyclopropyl)methanone; or
- 13 (K) Unclassified Synthetic Cannabinoids, including without
14 limitation the following:
- 15 (i) CP 50556-1 hydrochloride, or [(6S,6aR,9R,10aR)-
16 9-hydroxy-6-methyl-3-[(2R)-5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-
17 octahydrophenanthridin-1-yl] acetate;
- 18 (ii) HU-210, or (6aR,10aR)-9-(hydroxymethyl)-6,6-
19 dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
- 20 (iii) HU-211, or Dexanabinol,(6aS,10aS)-9-
21 (hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-
22 tetrahydrobenzo[c]chromen-1-ol;
- 23 (iv) Dimethylheptylpyran or DMHP;
- 24 (v) WIN55,212-2, or 2,3-Dihydro-5-methyl-3-(4-
25 morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl-1-
26 naphthalenylmethanone;
- 27 (vi) URB-597, or [3-(3-carbamoylphenyl)phenyl] N-
28 cyclohexylcarbamate;
- 29 (vii) URB 754, or 6-methyl-2-[(4-methylphenyl)amino]-
30 1-benzoxazin-4-one;
- 31 (viii) AKB-48, or N-(1-adamantyl)-1-pentylindazole-
32 3-carboxamide;
- 33 (ix) CB 13, or 1-naphthalenyl[4-(pentyloxy)-1-
34 naphthalenyl]-methanone;
- 35 (x) URB 602, or cyclohexyl N-(3-
36 phenylphenyl)carbamate;

1 (xi) PB-22, or quinolin-8-yl 1-(5-pentyl)-1H-indole-
 2 3-carboxylate;

3 (xii) 5FPB-22, or quinolin-8-yl 1-(5-fluoropentyl)-
 4 1H-indole-3-carboxylate;

5 (xiii) BB-22, or quinolin-8-yl 1-(cyclohexylmethyl)-
 6 1H-indole-3-carboxylate;

7 (xiv) NNEI (MN-24), or N-1-naphthalenyl-1-pentyl-1H-
 8 indole-3-carboxamide; and

9 (xv) 5F-NNEI, or 1-(5-fluoropentyl)-N-(naphthalen-1-
 10 yl)-1H-indole-3-carboxamide; or

11 (6) A synthetic substance, derivative, or its isomers with:

12 (A) Similar chemical structure to any substance described
 13 in subdivisions ~~(a)(1)-(4)~~ (a)(1)-(5) of this section; or

14 (B) Similar pharmacological ~~activity effects~~ activity effects to any
 15 substance described in subdivisions ~~(a)(1)-(4)~~ (a)(1)-(5) of this section.
 16 ~~such as the following:~~

17 ~~(i) [] 1-cis or trans tetrahydrocannabinol, and its~~
 18 ~~optical isomers;~~

19 ~~(ii) [] 6-cis or trans tetrahydrocannabinol, and~~
 20 ~~its optical isomers; and~~

21 ~~(iii) [] 3.4-cis or trans tetrahydrocannabinol,~~
 22 ~~and its optical isomers.~~

23 (b) However, ~~the Director of the Department of Health~~ director shall
 24 not delete a controlled substance listed in this section from Schedule VI.

25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36